期刊
CLINICAL & TRANSLATIONAL ONCOLOGY
卷 11, 期 8, 页码 499-510出版社
SPRINGER INTERNATIONAL PUBLISHING AG
DOI: 10.1007/s12094-009-0394-y
关键词
Interstitial lung disease; Pulmonary fibrosis; Sirolimus; ROS; Rapamycin
类别
资金
- Coruna University Hospital Foundation
- Instituto de Salud Carlos III (Spanish Government)
Interstitial lung disease is a rare side effect of temsirolimus treatment in renal cancer patients. Pulmonary fibrosis is characterised by the accumulation of extracellular matrix collagen, fibroblast proliferation and migration, and loss of alveolar gas exchange units. Previous studies of pulmonary fibrosis have mainly focused on the fibro-proliferative process in the lungs. However, the molecular mechanism by which sirolimus promotes lung fibrosis remains elusive. Here, we propose an overall cascade hypothesis of interstitial lung diseases that represents a common, partly underlying synergism among them as well as the lung pathogenesis side effects of mammalian target of rapamycin inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据